Investigational Oral Agent Muvalaplin Reduces Lp(a) by Up to 85% in High-Risk Adults: Phase 2 Data
Lp(a) is a genetically-driven and independent risk factor for CVD with no approved treatments. Lilly is advancing muvalaplin and has some good competition.
Budesonide-Based Triple Therapy Most Cost-Effective vs Dual Therapy for COPD
A new analysis found triple therapy for COPD, particularly B/G/F, more cost-effective vs dual therapy in terms of exacerbations and quality-adjusted life years.
Nobel Prize Awarded to Scientists Whose Work on mRNA Led to Development of COVID-19 Vaccines
The pair of scientists was cited "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19."
Worldwide Burden of Atrial Fibrillation More Than Doubled Over 30 Years: Global Analysis
Atrial fibrillation prevalence is rising across socioeconomic strata globally, the new analysis finds, with effects of BMI, ETOH, and sedentary behavior shifting as key drivers.
Frail Elderly at High Risk of Bleeding Following VKA-DOAC Switch: Surprise Outcome Shared at ESC Congress
Oldest and most frail elderly were at more than 60% greater risk of bleeding when switched from a VKA than those who remained on the traditional agent.
